FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979465918> ?p ?o ?g. }

• W2979465918 abstract "Abstract Abstract 1686 Poster Board I-712 Introduction Premature senescence, a terminal cell-cycle arrest condition, reflects an acute cellular stress response upon a variety of cellular insults including oncogene activation and chemotherapeutic DNA damage. Therefore, senescence potentially complements apoptosis as a safeguard program and tumor-suppressive mechanism. Although it is frequently observed in the clinic that patients who only achieve disease stabilization or partial remission in response to chemotherapy may experience lasting freedom from progression, no tumor model has shown that therapy-induced senescence (TIS) significantly contributes to treatment outcome. Here, we employ the Eμ-myc mouse lymphoma model with and without intact alleles of the histone H3 lysine 9 (H3K9) methyltransferase Suv39h1 (controlling senescence) and of p53 (mediating both apoptosis and senescence) to demonstrate a critical role for senescence in cancer therapy in vivo. Methods Lymphoma cells (LCs), retrovirally transduced with bcl2 to block apoptosis, were treated with the DNA damaging anticancer agent adriamycin (ADR) in vitro, or were exposed to the alkylating agent cyclophosphamide upon lymphoma formation in normal immunocompetent mice in vivo. TIS was analyzed by senescence-associated β-galactosidase activity (SA-β-gal), Ki67 staining and BrdU incorporation. Tumor formation, therapy and progression in vivo was monitored by whole body fluorescence and luciferase imaging and 18F-fluoro-deoxyglucose (FDG) and 18F-fluoro-deoxythymidine (FLT) positron emission tomography (PET). Time-course analysis of glucose and oxygen consumption rates and NAD(P)/NAD(P)H ratios over time were used to define a senescence energy consumption profile. Progression-free and overall survival was evaluated using the Kaplan-Meier method. Results Bcl2-protected control (i.e. no further defined genetic defects) LCs, but not Suv39h1- or p53-deficient LCs, enter TIS in vivo as evidenced by uniform SA-β-gal reactivity, high frequency of H3K9-trimethylation-positive cells, and loss of Ki67 staining and BrdU incorporation due to a cell-cycle block in the G1-phase. Notably, Suv39h1- lymphomas recapitulate the proliferation rate and sensitivity to drug-induced apoptosis of control lymphomas, but display significantly shorter progression-free and overall survival after chemotherapy in vivo. Despite their stable growth arrest ADR-senescent control;bcl2 lymphomas exhibited higher glucose metabolism and energy consumption in vitro when compared to their untreated counterparts or senescence-refractory, ADR-treated Suv39h1-;bcl2 lymphomas. Accordingly, TIS LCs can be non-invasively detected by a discordant positive FDG- but negative FLT-PET scan. Discussion: The study demonstrates that Suv39h1 acts as an essential mediator of TIS without compromising apoptosis or altering the proliferative capacity of lymphoma cells. Myc-driven lymphomas senesce in response to DNA damaging anticancer therapies, but display high levels of glucose metabolism. Therefore, they can be detected by FDG-PET despite their resting condition, indicating that a positive post-therapy FDG-PET scan in the clinic does not necessarily reflect a growing tumor lesion. In vivo, Bcl2-protected Suv39h1- lymphoma-bearing mice succumb dramatically fast to their disease after chemotherapy reminiscent of p53null lymphoma-bearing mice. Hence, Suv39h1-controlled TIS is a critical component of anticancer drug therapy in vivo and significantly extends progression-free and overall survival of the host. Disclosures No relevant conflicts of interest to declare." @default.
• W2979465918 created "2019-10-18" @default.
• W2979465918 creator A5013313803 @default.
• W2979465918 creator A5021273661 @default.
• W2979465918 creator A5028510513 @default.
• W2979465918 creator A5056103726 @default.
• W2979465918 creator A5074463005 @default.
• W2979465918 creator A5085482577 @default.
• W2979465918 creator A5086465315 @default.
• W2979465918 date "2009-11-20" @default.
• W2979465918 modified "2023-10-02" @default.
• W2979465918 title "Loss of Therapy-Induced Senescence in Myc-Driven Lymphomas Compromises Treatment Outcome In Vivo." @default.
• W2979465918 doi "https://doi.org/10.1182/blood.v114.22.1686.1686" @default.
• W2979465918 hasPublicationYear "2009" @default.
• W2979465918 type Work @default.
• W2979465918 sameAs 2979465918 @default.
• W2979465918 citedByCount "0" @default.
• W2979465918 crossrefType "journal-article" @default.
• W2979465918 hasAuthorship W2979465918A5013313803 @default.
• W2979465918 hasAuthorship W2979465918A5021273661 @default.
• W2979465918 hasAuthorship W2979465918A5028510513 @default.
• W2979465918 hasAuthorship W2979465918A5056103726 @default.
• W2979465918 hasAuthorship W2979465918A5074463005 @default.
• W2979465918 hasAuthorship W2979465918A5085482577 @default.
• W2979465918 hasAuthorship W2979465918A5086465315 @default.
• W2979465918 hasConcept C126322002 @default.
• W2979465918 hasConcept C143998085 @default.
• W2979465918 hasConcept C203014093 @default.
• W2979465918 hasConcept C207001950 @default.
• W2979465918 hasConcept C2779338263 @default.
• W2979465918 hasConcept C502942594 @default.
• W2979465918 hasConcept C522857546 @default.
• W2979465918 hasConcept C54355233 @default.
• W2979465918 hasConcept C71924100 @default.
• W2979465918 hasConcept C86803240 @default.
• W2979465918 hasConceptScore W2979465918C126322002 @default.
• W2979465918 hasConceptScore W2979465918C143998085 @default.
• W2979465918 hasConceptScore W2979465918C203014093 @default.
• W2979465918 hasConceptScore W2979465918C207001950 @default.
• W2979465918 hasConceptScore W2979465918C2779338263 @default.
• W2979465918 hasConceptScore W2979465918C502942594 @default.
• W2979465918 hasConceptScore W2979465918C522857546 @default.
• W2979465918 hasConceptScore W2979465918C54355233 @default.
• W2979465918 hasConceptScore W2979465918C71924100 @default.
• W2979465918 hasConceptScore W2979465918C86803240 @default.
• W2979465918 hasLocation W29794659181 @default.
• W2979465918 hasOpenAccess W2979465918 @default.
• W2979465918 hasPrimaryLocation W29794659181 @default.
• W2979465918 hasRelatedWork W1956409007 @default.
• W2979465918 hasRelatedWork W1972658902 @default.
• W2979465918 hasRelatedWork W1990161819 @default.
• W2979465918 hasRelatedWork W2008253268 @default.
• W2979465918 hasRelatedWork W2018577785 @default.
• W2979465918 hasRelatedWork W2037731733 @default.
• W2979465918 hasRelatedWork W2084839831 @default.
• W2979465918 hasRelatedWork W2520183158 @default.
• W2979465918 hasRelatedWork W2561396377 @default.
• W2979465918 hasRelatedWork W2906031490 @default.
• W2979465918 hasRelatedWork W2912733164 @default.
• W2979465918 hasRelatedWork W2954196736 @default.
• W2979465918 hasRelatedWork W2982349735 @default.
• W2979465918 hasRelatedWork W3003097831 @default.
• W2979465918 hasRelatedWork W3038217579 @default.
• W2979465918 hasRelatedWork W3044002025 @default.
• W2979465918 hasRelatedWork W3083348738 @default.
• W2979465918 hasRelatedWork W3118207884 @default.
• W2979465918 hasRelatedWork W3198288648 @default.
• W2979465918 hasRelatedWork W3213770750 @default.
• W2979465918 isParatext "false" @default.
• W2979465918 isRetracted "false" @default.
• W2979465918 magId "2979465918" @default.
• W2979465918 workType "article" @default.